Literature DB >> 25114143

Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice.

Andrés Pizzorno1, Yacine Abed1, Pier-Luc Plante1, Julie Carbonneau1, Mariana Baz1, Marie-Ève Hamelin1, Jacques Corbeil1, Guy Boivin2.   

Abstract

The evolution of oseltamivir resistance mutations during selection through serial passages in animals is still poorly described. Herein, we assessed the evolution of neuraminidase (NA) and hemagglutinin (HA) genes of influenza A/WSN/33 (H1N1) and A/Victoria/3/75 (H3N2) viruses recovered from the lungs of experimentally infected BALB/c mice receiving suboptimal doses (0.05 and 1 mg/kg of body weight/day) of oseltamivir over two generations. The traditional phenotypic and genotypic methods as well as deep-sequencing analysis were used to characterize the potential selection of mutations and population dynamics of oseltamivir-resistant variants. No oseltamivir-resistant NA or HA changes were detected in the recovered A/WSN/33 viruses. However, we observed a positive selection of the I222T NA substitution in the recovered A/Victoria/3/75 viruses, with a frequency increasing over time and with an oseltamivir concentration from 4% in the initial pretherapy inoculum up to 28% after two lung passages. Although the presence of mixed I222T viral populations in mouse lungs only led to a minimal increase in oseltamivir 50% enzyme-inhibitory concentrations (IC50s) (by a mean of 5.7-fold) compared to that of the baseline virus, the expressed recombinant A/Victoria/3/75 I222T NA protein displayed a 16-fold increase in the oseltamivir IC50 level compared to that of the recombinant wild type (WT). In conclusion, the combination of serial in vivo passages under neuraminidase inhibitor (NAI) pressure and temporal deep-sequencing analysis enabled, for the first time, the identification and selection of the oseltamivir-resistant I222T NA mutation in an influenza H3N2 virus. Additional in vivo selection experiments with other antivirals and drug combinations might provide important information on the evolution of antiviral resistance in influenza viruses.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25114143      PMCID: PMC4249448          DOI: 10.1128/AAC.02956-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.

Authors:  Andrew J Burnham; Tatiana Baranovich; Bindumadhav M Marathe; Jianling Armstrong; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

2.  Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2012-09-28

3.  Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets.

Authors:  Yacine Abed; Andrés Pizzorno; Xavier Bouhy; Chantal Rhéaume; Guy Boivin
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

4.  Ray Meta: scalable de novo metagenome assembly and profiling.

Authors:  Sébastien Boisvert; Frédéric Raymond; Elénie Godzaridis; François Laviolette; Jacques Corbeil
Journal:  Genome Biol       Date:  2012-12-22       Impact factor: 13.583

Review 5.  Influenza virus resistance to neuraminidase inhibitors.

Authors:  Mélanie Samson; Andrés Pizzorno; Yacine Abed; Guy Boivin
Journal:  Antiviral Res       Date:  2013-03-22       Impact factor: 5.970

6.  A conformational restriction in the influenza A virus neuraminidase binding site by R152 results in a combinational effect of I222T and H274Y on oseltamivir resistance.

Authors:  Lan Huang; Yang Cao; Jianfang Zhou; Kun Qin; Wenfei Zhu; Yun Zhu; Lei Yang; Dayan Wang; Hong Wei; Yuelong Shu
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

7.  Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance.

Authors:  Yunwen Hu; Shuihua Lu; Zhigang Song; Wei Wang; Pei Hao; Jianhua Li; Xiaonan Zhang; Hui-Ling Yen; Bisheng Shi; Tao Li; Wencai Guan; Lei Xu; Yi Liu; Sen Wang; Xiaoling Zhang; Di Tian; Zhaoqin Zhu; Jing He; Kai Huang; Huijie Chen; Lulu Zheng; Xuan Li; Jie Ping; Bin Kang; Xiuhong Xi; Lijun Zha; Yixue Li; Zhiyong Zhang; Malik Peiris; Zhenghong Yuan
Journal:  Lancet       Date:  2013-05-29       Impact factor: 79.321

8.  Emergence of an oseltamivir-resistant influenza A/H3N2 virus in an elderly patient receiving a suboptimal dose of antiviral prophylaxis.

Authors:  Jean-François Roussy; Yacine Abed; Xavier Bouhy; Guy Boivin
Journal:  J Clin Microbiol       Date:  2013-10-02       Impact factor: 5.948

9.  Oseltamivir-resistant influenza A(H1N1)pdm09 virus in Dutch travellers returning from Spain, August 2012.

Authors:  A Meijer; M Jonges; P van Beek; C M Swaan; A D Osterhaus; R S Daniels; A C Hurt; M P Koopmans
Journal:  Euro Surveill       Date:  2012-09-06

10.  Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.

Authors:  H-L Yen; J L McKimm-Breschkin; K-T Choy; D D Y Wong; P P H Cheung; J Zhou; I H Ng; H Zhu; R J Webby; Y Guan; R G Webster; J S M Peiris
Journal:  MBio       Date:  2013-07-16       Impact factor: 7.867

View more
  9 in total

1.  Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses.

Authors:  Xin Zhao; Runfeng Li; Yang Zhou; Mengjie Xiao; Chunlong Ma; Zhongjin Yang; Shaogao Zeng; Qiuling Du; Chunguang Yang; Haiming Jiang; Yanmei Hu; Kefeng Wang; Chris Ka Pun Mok; Ping Sun; Jianghong Dong; Wei Cui; Jun Wang; Yaoquan Tu; Zifeng Yang; Wenhui Hu
Journal:  J Med Chem       Date:  2018-06-11       Impact factor: 7.446

2.  Molecular surveillance of antiviral drug resistance of influenza A/H3N2 virus in Singapore, 2009-2013.

Authors:  Hong Kai Lee; Julian Wei-Tze Tang; Tze Ping Loh; Aeron C Hurt; Lynette Lin-Ean Oon; Evelyn Siew-Chuan Koay
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

3.  Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.

Authors:  Henju Marjuki; Vasiliy P Mishin; Anton P Chesnokov; Juan A De La Cruz; Charles T Davis; Julie M Villanueva; Alicia M Fry; Larisa V Gubareva
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

4.  Heterosubtypic protection conferred by the human monoclonal antibody PN-SIA28 against influenza A virus lethal infections in mice.

Authors:  Miguel Retamal; Yacine Abed; Chantal Rhéaume; Francesca Cappelletti; Nicola Clementi; Nicasio Mancini; Massimo Clementi; Roberto Burioni; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

5.  Recombinant influenza virus with a pandemic H2N2 polymerase complex has a higher adaptive potential than one with seasonal H2N2 polymerase complex.

Authors:  Alex W H Chin; Hui-L Yen; Scott Krauss; Richard J Webby; Leo L M Poon
Journal:  J Gen Virol       Date:  2015-12-24       Impact factor: 3.891

6.  Influenza A(H7N9) virus acquires resistance-related neuraminidase I222T substitution when infected mallards are exposed to low levels of oseltamivir in water.

Authors:  Anna Gillman; Marie Nykvist; Shaman Muradrasoli; Hanna Söderström; Michelle Wille; Annika Daggfeldt; Caroline Bröjer; Jonas Waldenström; Björn Olsen; Josef D Järhult
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

7.  Seasonal Genetic Drift of Human Influenza A Virus Quasispecies Revealed by Deep Sequencing.

Authors:  Cyril Barbezange; Louis Jones; Hervé Blanc; Ofer Isakov; Gershon Celniker; Vincent Enouf; Noam Shomron; Marco Vignuzzi; Sylvie van der Werf
Journal:  Front Microbiol       Date:  2018-10-31       Impact factor: 5.640

8.  Lack of selective resistance of influenza A virus in presence of host-targeted antiviral, UV-4B.

Authors:  Kelly L Warfield; Kaitlyn R Schaaf; Lisa Evans DeWald; Kevin B Spurgers; Wei Wang; Eric Stavale; Michelle Mendenhall; Meghan H Shilts; Timothy B Stockwell; Dale L Barnard; Urban Ramstedt; Suman R Das
Journal:  Sci Rep       Date:  2019-05-16       Impact factor: 4.379

9.  The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses.

Authors:  Wei Xu; Shuai Xia; Jing Pu; Qian Wang; Peiyu Li; Lu Lu; Shibo Jiang
Journal:  Front Microbiol       Date:  2018-11-06       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.